MONISTAT 5 (miconazole nitrate) by Personal Genomics is clinical pharmacology miconazole nitrate exhibits fungicidal activity in vitro against species of the genus candida. First approved in 1989.
Drug data last refreshed 22h ago · AI intelligence enriched 1w ago
MONISTAT 5 (miconazole nitrate) is a vaginal antifungal suppository approved in 1989 for the treatment of vulvovaginal candidiasis. The drug exhibits fungicidal activity against Candida species through an unknown pharmacologic mechanism. It is administered intravaginally with minimal systemic absorption.
Product is in late-stage lifecycle with limited commercial growth potential, suggesting smaller brand team and transition focus toward LOE planning.
CLINICAL PHARMACOLOGY Miconazole nitrate exhibits fungicidal activity in vitro against species of the genus Candida. The pharmacologic mode of action is unknown. Following intravaginal administration of miconazole nitrate, small amounts are absorbed. Administration of a single dose of miconazole…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Prospective Two-Year Study to Assess Miconazole Nitrate Resistance in Neonates and Infants
Worked on MONISTAT 5 at Personal Genomics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
MONISTAT 5 offers limited career advancement prospects due to its LOE-approaching lifecycle and minimal linked job opportunities. Roles are primarily focused on defensive market share management and OTC channel strategy rather than growth-oriented innovation.